Journal
CANCER INVESTIGATION
Volume 30, Issue 10, Pages 727-731Publisher
INFORMA HEALTHCARE
DOI: 10.3109/07357907.2012.732163
Keywords
Drozitumab; Metastatic colorectal cancer; Apo2 ligand; Apoptosis; Toxicity; Efficacy
Categories
Funding
- Genentech, Inc.
Ask authors/readers for more resources
In this multicenter phase Ib study, drozitumab was given in combination with the mFOLFOX6 regimen and bevacizumab in patients with previously untreated, locally advanced recurrent or metastatic colorectal cancer on day 1 of every 14-day cycle. Nine patients were treated at 2 different cohort dose levels of drozitumab. No dose-limiting toxicities occurred at either dose level and the maximum tolerated dose was not reached. Two patients had a partial response of 4.93 and 4.96 months duration. Cohort 2 dose level is the recommended starting dose level for future trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available